ArriVent BioPharma, Inc. (AVBP) Cash Flow Statement
ArriVent BioPharma, Inc. (AVBP) generated -$147.9M of operating cash flow over the twelve months to 2026-06-30, spent $0 on capital expenditure and had free cash flow of -$147.9M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AVBPArriVent BioPharma, Inc.Follow AVBP — free
—
Price chart with a free account
- Market cap
- 1.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating cash flow | -70.2 | -160.6 | -147.9 | |
| Capital expenditure | 0.0 | 0.0 | -0.0 | |
| Free cash flow | -70.2 | -160.6 | -147.9 | |
| Stock-based compensation | 3.2 | 12.5 | — |
USD millions · SEC XBRL
ArriVent BioPharma, Inc. — questions
- What is ArriVent BioPharma, Inc.'s operating cash flow?
- -$147.9M over the twelve months to 2026-06-30.
- How much does ArriVent BioPharma, Inc. spend on capital expenditure?
- $0 over the twelve months to 2026-06-30.
- What is ArriVent BioPharma, Inc.'s free cash flow?
- -$147.9M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from ArriVent BioPharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.